Risks of Hormone Replacement Therapy for Men: What You Need to Know

Last Updated: August 1, 2026

What Is Testosterone Replacement Therapy and Why Men Use It

Testosterone replacement therapy is a medical treatment in which men receive supplemental testosterone through injections, gels, patches, or pellets to raise their serum testosterone levels. Men pursue TRT when their body produces insufficient testosterone, a condition called hypogonadism, or when they experience symptoms associated with low testosterone, such as fatigue, reduced libido, erectile dysfunction, or mood changes. At Ascend Vitality, we recognize that understanding the risks of hormone replacement therapy for men requires first understanding why men seek this treatment and what the therapy actually involves.

The appeal of testosterone replacement therapy is straightforward: raising testosterone can improve energy, sexual function, muscle mass, and mood in men with clinically low levels. However, the risks of hormone replacement therapy for men extend well beyond the initial appeal. Men considering TRT often focus on the benefits without fully grasping the potential cardiovascular, hematologic, and metabolic complications that can emerge during treatment. According to recent clinical guidance, many men initiating TRT do so without adequate baseline screening or ongoing clinical monitoring, which significantly amplifies their risk profile.

TRT works by delivering exogenous testosterone, synthetic or bioidentical hormones, into the body to supplement or replace the testosterone that the endocrine system fails to produce adequately. This differs fundamentally from optimizing a man’s natural endogenous testosterone production through lifestyle changes. The distinction matters because exogenous supplementation bypasses the body’s normal feedback mechanisms, potentially disrupting hormone regulation and creating imbalances that persist even after treatment stops.

TRT Administration Method	Frequency	Typical Dose Range	Onset of Effect
Injectable (IM or SC)	Weekly to every 2 weeks	50-100 mg weekly	24-48 hours
Transdermal gel	Daily	50-100 mg daily	3-5 days
Transdermal patch	Daily	2-6 mg daily	3-5 days
Pellets (subcutaneous)	Every 3-4 months	150-450 mg per insertion	5-7 days

Men with documented hypogonadism, confirmed by low serum testosterone levels (typically below 300 ng/dL) and clinical symptoms, represent the clearest candidates for TRT. Yet the boundary between therapeutic use and supraphysiologic dosing has blurred in recent years, particularly in the wellness and anti-aging space. When testosterone levels climb above the normal physiologic range, adverse events multiply significantly.

Testosterone Replacement Therapy Side Effects: The Full Picture

The side effects of testosterone replacement therapy span multiple organ systems and can emerge at different timescales. Some effects appear within weeks; others develop over months or years of treatment. Understanding this spectrum is essential because many men experience mild early side effects and assume they will resolve, only to face serious complications later.

Common Physical Side Effects

Acne ranks among the most visible and common side effects of TRT. Testosterone stimulates sebaceous gland activity and increases skin oil production, creating an environment where acne bacteria thrive. Acne typically appears on the chest, back, and shoulders, areas with high sebaceous gland density. For some men, acne is cosmetic and manageable; for others, it becomes severe enough to require dermatologic intervention or treatment discontinuation.

Fluid retention and peripheral edema occur because testosterone enhances sodium reabsorption in the kidneys and increases aldosterone sensitivity. Men on TRT frequently report swelling in the ankles, feet, and hands. This is not merely cosmetic, fluid retention increases blood volume and places additional strain on the cardiovascular system, raising blood pressure and exacerbating existing hypertension. Men with a history of heart failure or kidney disease face substantially elevated risk from this effect.

Testicular atrophy is an inevitable consequence of sustained exogenous testosterone therapy. When external testosterone floods the system, the pituitary gland suppresses luteinizing hormone (LH) and follicle-stimulating hormone (FSH) signaling. Without LH and FSH, the testes cease spermatogenesis and gradually shrink. This atrophy is typically reversible if TRT is discontinued and endogenous hormone production resumes, but recovery can take months to years. For men concerned about fertility, testicular atrophy represents a significant trade-off.

Polycythemia, an elevation in red blood cell count and hematocrit levels, develops in a meaningful proportion of men on TRT. Testosterone stimulates erythropoietin production in the kidneys, driving increased red blood cell production. While the body needs red blood cells for oxygen transport, excessive red blood cells thicken the blood, increasing blood viscosity. This thickening raises the risk of thrombosis (blood clots), stroke, and myocardial infarction, particularly in men over 50 or those with underlying cardiovascular risk factors.

Mood and Psychological Changes

Mood swings and emotional volatility occur in some men during the first weeks of TRT initiation. Rapid shifts in testosterone levels can destabilize mood regulation, leading to irritability, aggression, or emotional lability. These changes often stabilize as the body adjusts, but they can be severe enough to affect relationships and work performance during the adjustment period.

The psychological impact of discontinuation deserves more attention than it typically receives. Men who experience the energy boost, improved libido, and enhanced mood from TRT often struggle emotionally when stopping treatment. The return to baseline testosterone levels feels like a crash, triggering depression, fatigue, and sexual dysfunction that can last weeks or months. This discontinuation effect can create psychological dependence on TRT, making it difficult for men to stop even when medical reasons warrant cessation.

TRT Risks and Benefits: Weighing the Trade-offs

The decision to pursue testosterone replacement therapy should rest on a clear-eyed assessment of what TRT actually delivers against what it risks. The benefits are real but often overstated in marketing and wellness contexts. The risks are serious and sometimes irreversible.

Benefits of TRT (when testosterone is genuinely deficient):

• Improved energy and sense of well-being in men with documented hypogonadism
• Enhanced sexual function and libido restoration
• Increased lean muscle mass and strength (when combined with resistance training)
• Potential improvement in bone mineral density
• Mood stabilization in men whose depression correlates with low testosterone

Risks of TRT (apply to most men receiving treatment):

• Cardiovascular events including myocardial infarction and stroke
• Polycythemia and increased thrombotic risk
• Worsening or development of sleep apnea
• Prostate-related complications and potential acceleration of prostate cancer
• Fluid retention and hypertension
• Testicular atrophy and infertility
• Gynecomastia requiring potential surgical intervention
• Hepatic dysfunction in men using oral testosterone formulations
• Psychological dependence and difficult discontinuation

The asymmetry between benefits and risks becomes apparent when you examine long-term outcomes. Short-term improvements in energy and sexual function are genuine, but they do not necessarily translate into better health outcomes or longevity. In fact, research from clinical long-term TRT outcome studies suggests that cardiovascular risk may offset quality-of-life improvements in certain populations.

Cardiovascular Health and Hormone Replacement Therapy Risks

Cardiovascular complications represent the most serious risks of hormone replacement therapy for men. The mechanism is multifactorial: testosterone increases red blood cell production (raising hematocrit and blood viscosity), promotes sodium retention (elevating blood pressure), and may directly affect vascular endothelial function. The result is a higher risk of myocardial infarction, ischemic stroke, and other thrombotic events.

Men over 50, those with existing hypertension, diabetes, or a personal or family history of early cardiac events face substantially elevated risk. Even young men with no apparent cardiovascular risk factors can experience adverse cardiac events when testosterone levels climb into the supraphysiologic range. Research from The Testosterone in Older Men with Mobility Limitations (TOM) trial documented increased cardiovascular events in older men receiving TRT, leading to early termination of the study.

Blood pressure elevation occurs in a significant percentage of men on TRT, particularly those receiving higher doses or those with baseline hypertension. The mechanism involves both fluid retention and direct vascular effects of testosterone. For men already on antihypertensive medications, TRT often necessitates dose escalation of blood pressure drugs or addition of additional agents.

Hematocrit monitoring becomes essential during TRT, yet many men receive inadequate clinical oversight. Hematocrit above 54% substantially increases thrombotic risk and warrants intervention, either dose reduction, phlebotomy, or discontinuation. Men receiving TRT should have hematocrit checked every 3-6 months, yet many practitioners fail to implement this standard.

Prostate Health Concerns With Testosterone Therapy

The relationship between testosterone and prostate cancer remains controversial, but the precautionary principle should guide clinical decision-making. Testosterone does not cause prostate cancer in men without pre-existing disease, but it may accelerate growth of existing, undetected prostate cancers. This is why baseline prostate-specific antigen (PSA) testing and digital rectal examination are essential before initiating TRT.

Men with a personal or family history of prostate cancer, elevated baseline PSA levels, or suspicious digital rectal exam findings should avoid TRT altogether. For men without these risk factors, PSA monitoring during TRT is mandatory. PSA elevation during treatment warrants urologic evaluation to exclude malignancy. Some men experience PSA elevation that settles with dose reduction or discontinuation; others face a diagnosis of prostate cancer that might have remained dormant had testosterone not been supplemented.

Benign prostatic hyperplasia (BPH) frequently worsens on TRT. Men with baseline lower urinary tract symptoms, hesitancy, frequency, nocturia, often experience exacerbation requiring additional treatment or TRT discontinuation. The mechanism involves testosterone’s direct effects on prostate smooth muscle and epithelial growth.

Long-Term Effects of TRT: What Research Shows

The long-term safety profile of testosterone replacement therapy remains incompletely understood because most men have not been followed for decades on continuous therapy. What we do know comes from smaller observational studies, case reports, and the clinical experience of practitioners managing patients over years or decades.

Men who remain on TRT for 5+ years show persistent risks of polycythemia, hypertension, and prostate complications. The longer a man receives supraphysiologic testosterone, the greater the cumulative risk of thrombotic events. Cardiovascular event rates do not plateau; they continue to accumulate with time on therapy.

Testicular atrophy and infertility persist as long as TRT continues. Men hoping to father biological children while on TRT face a difficult choice: either discontinue therapy (with all the attendant mood and sexual side effects) or pursue fertility preservation through sperm banking before initiating treatment. Recovery of spermatogenesis after discontinuation is possible but not guaranteed, and it can take 6-12 months or longer.

Bone mineral density changes occur during long-term TRT. While some studies suggest improved bone density, others document accelerated bone loss in certain skeletal sites. The net effect on fracture risk remains unclear, particularly in older men where TRT-induced polycythemia and hypertension may offset any skeletal benefit.

Metabolic syndrome and lipid abnormalities can develop or worsen during TRT. Some men experience elevation in triglycerides and LDL cholesterol while on therapy, particularly at higher doses. This metabolic derangement compounds cardiovascular risk.

Testosterone Therapy Contraindications: Who Shouldn’t Use TRT

Absolute contraindications to testosterone replacement therapy exist and should be respected without exception.

Men who should NOT receive TRT:

• History of prostate cancer (any stage, any time since diagnosis)
• Elevated PSA levels without urologic clearance
• Suspicious digital rectal exam findings
• Untreated or inadequately controlled sleep apnea
• Severe polycythemia (hematocrit >54%)
• Uncontrolled hypertension
• Recent myocardial infarction or stroke
• Severe hepatic dysfunction
• Severe renal impairment
• Desire for fertility in the near term without sperm banking

Relative contraindications (require specialist consultation and careful monitoring):

• Age over 70 without clear hypogonadal symptoms
• Existing cardiovascular disease or multiple cardiovascular risk factors
• Baseline hypertension on multiple medications
• Baseline sleep apnea (even if treated)
• Baseline polycythemia or hematologic disorders
• History of thrombosis or thrombophilia
• Severe obesity (BMI >35)
• Metabolic syndrome

Men in the relative contraindication category may still benefit from TRT, but the decision requires detailed risk-benefit discussion, baseline comprehensive screening, and more frequent clinical monitoring than standard practice provides.

Managing Risks: Clinical Monitoring and Lifestyle Strategies

Minimizing the risks of hormone replacement therapy for men requires rigorous baseline assessment, appropriate dose selection, and ongoing clinical monitoring. Many men receive TRT without adequate safeguards; this section outlines what responsible TRT management should include.

Baseline assessment before initiating TRT should include:

• Comprehensive metabolic panel (liver and kidney function)
• Lipid panel
• Hematocrit and hemoglobin
• PSA level and digital rectal examination
• Cardiovascular risk assessment (blood pressure, EKG if indicated)
• Sleep apnea screening (STOP-BANG questionnaire minimum)
• Detailed symptom assessment and documentation
• Confirmation of hypogonadism with at least two morning serum testosterone measurements

Ongoing monitoring during TRT (minimum frequency):

• Serum testosterone level every 6-8 weeks until stable, then annually
• Hematocrit every 3-6 months for the first year, then annually
• PSA annually (or more frequently if baseline elevated or rising)
• Blood pressure at each visit
• Lipid panel annually
• Liver function tests annually
• Symptom assessment and side effect screening at each visit

Dose optimization matters enormously. The goal should be to achieve serum testosterone in the low-normal range (300-500 ng/dL), not to chase supraphysiologic levels. Many men and their providers mistakenly believe that higher testosterone levels produce better results; in reality, supraphysiologic dosing dramatically increases adverse event risk without proportional benefit. Starting low and titrating slowly allows identification of the minimum effective dose.

Lifestyle strategies that reduce TRT-related risks:

Regular aerobic exercise reduces cardiovascular risk, blood pressure, and polycythemia risk. Men on TRT should engage in 150 minutes of moderate-intensity aerobic activity weekly. Resistance training builds muscle and may improve bone density, but it should be balanced with cardiovascular exercise, not replace it.

Dietary sodium restriction helps mitigate fluid retention and hypertension. Men prone to edema should limit sodium intake to less than 2,300 mg daily. Adequate hydration supports cardiovascular health, though excessive hydration offers no additional benefit.

Sleep apnea screening and treatment are non-negotiable. TRT worsens sleep apnea, so baseline screening with a validated tool (STOP-BANG questionnaire) should precede TRT initiation. Men with diagnosed sleep apnea require treatment (CPAP, oral appliance, or positional therapy) before and during TRT.

Smoking cessation eliminates a major independent cardiovascular risk factor. Men on TRT who smoke face compounded thrombotic and cardiac risk that is difficult to quantify but clearly substantial.

Regular clinical follow-up with a provider experienced in TRT management ensures that emerging complications are detected early. Men receiving TRT from non-specialists or through online-only platforms without strong monitoring protocols face substantially elevated risk.

Conclusion

The risks of hormone replacement therapy for men are substantial, multisystem, and sometimes irreversible. While TRT offers genuine benefits for men with documented hypogonadism, those benefits must be weighed against cardiovascular complications, polycythemia, prostate concerns, testicular atrophy, and the difficult psychological transition if treatment is discontinued.

Many men pursue TRT without adequate baseline screening or realistic understanding of long-term risks. Online platforms and wellness clinics often prioritize convenience and patient satisfaction over rigorous safety protocols. Ascend Vitality emphasizes that responsible hormone therapy requires comprehensive baseline assessment, individualized dose optimization, and ongoing clinical monitoring. When you work with Ascend Vitality, you receive medically-supported programs with qualified provider oversight, clinical-grade monitoring protocols, and transparent communication about both benefits and risks. The goal is not maximum testosterone levels, it’s optimized health outcomes with careful risk mitigation.

If you’re considering testosterone replacement therapy, start with a thorough conversation with a qualified healthcare provider. Request baseline labs, understand your personal risk profile, and commit to ongoing monitoring. Your long-term health depends on it. American Urological Association clinical guidelines on testosterone deficiency provide evidence-based recommendations for patient evaluation and treatment.

Frequently Asked Questions

What are the serious side effects of testosterone replacement therapy?

Serious side effects of TRT include cardiovascular events such as heart attack and stroke, particularly in men with existing heart disease. Polycythemia (elevated red blood cell count) thickens blood and increases clot risk. Prostate-related concerns include accelerated growth of existing cancer. Sleep apnea can worsen or develop. Testicular atrophy occurs as the body stops producing endogenous testosterone. Liver dysfunction may develop with oral formulations. Gynecomastia (breast tissue growth) and fluid retention also occur. Clinical monitoring through regular blood work and PSA testing helps catch these early.

Who should not take testosterone replacement therapy or TRT?

Men with untreated or uncontrolled prostate cancer should not use TRT, as testosterone fuels tumor growth. Those with a history of breast cancer, severe cardiovascular disease, or recent heart attack or stroke should avoid it. Men with untreated sleep apnea, severe liver disease, or polycythemia are contraindicated. Those allergic to testosterone or its delivery components should not use it. Men with a PSA above 4 ng/mL or rising PSA without investigation need clearance first. Anyone with supraphysiologic testosterone levels from prior use or with poor compliance for monitoring should discuss risks thoroughly with a qualified physician before starting.

What are the long-term effects of testosterone replacement therapy?

Long-term TRT effects depend on dosing, duration, and individual health factors. Sustained supraphysiologic dosing increases cardiovascular risk over years. Bone density typically improves with long-term TRT. Metabolic syndrome risk may increase if lifestyle factors worsen. Testicular function may not fully recover after years of therapy, affecting fertility. Prostate-specific antigen levels require ongoing monitoring, as some men experience PSA elevation. Mood and cognitive function often stabilize after initial adjustment. Hematocrit levels need periodic checks to prevent polycythemia. Discontinuation after years of use can trigger mood swings and fatigue as the body reestablishes endogenous testosterone production.

What is the difference between testosterone replacement therapy and other hormone treatments?

TRT restores testosterone to normal physiologic ranges in hypogonadal men, aiming to restore function rather than exceed it. Exogenous supplementation at supraphysiologic doses (above normal ranges) carries higher risks of side effects and adverse events. Androgen deprivation therapy, used in prostate cancer treatment, deliberately lowers testosterone to slow tumor growth and works through an opposite mechanism. Other hormone therapies target different hormones (thyroid, growth hormone, estrogen). TRT specifically addresses low testosterone through various delivery methods: injections, gels, patches, or pellets. The goal of replacement therapy is therapeutic restoration, whereas enhancement-focused approaches accept greater health risks for performance gains.